Genomic DNA was available from 31 patients who relapsed; paired diagnosis and haematological relapse samples were available from 8 patients and diagnostic material only from a further 23. We performed targeted nextgeneration sequencing of a panel of 60 genes frequently mutated in AML.
Molecular barcoded libraries were prepared using the HaloPlexHS sytem and sequenced using an Illumina HiSeq 2500 instrument. Alignment and variant calling was performed using Agilent SureCall v4 software. In parallel we performed PCR and fragment analysis to detect the FLT3 internal tandem duplication (ITD) as previously described. 3 . In keeping with previous reports, FLT3 ITD was the most frequent mutation and was detected in 14/31 patients (45%). Other recurrently mutated genes were WT1 in 7 patients (23%) NRAS in 3 (9.6%) and RUNX1 and KRAS in two patients each (6.4%). Profiling of the 5 patients who relapsed post salvage ATO showed no consistent findings, 2 had FLT3 ITDs, 1 had NRAS/KRAS mutations, 1 had a WT1 mutation and 1 had no mutations, suggesting that relapses post ATO are not predictable based on upfront genomic data.
The primary purpose of this updated analysis was to establish if an overall survival benefit for the ATO+ATRA has emerged as has been reported in the pivotal randomised APL0406 trial conducted in Italy and Germany by the GIMEMA, AML Study Group (AMLSG) and Study Alliance Leukaemia (SAL) cooperative groups 4, 5 In AML17 although we found that the combination of ATO and ATRA continues to show a very low risk of relapse (1% at 5 years)
irrespective of risk group with a significantly superior RFS compared to AIDA no overall survival benefit has emerged. These results are supported by a report from Abaza et al (2016) who also observed a very low relapse risk in both standard and high risk APL patients treated with ATO+ATRA supplemented by Gemtuzumab Ozogamicin (GO) in high risk patients 6 . In that study 46% of standard risk patients also received GO as treatment of leucocytosis, an intervention we used in only 6% of patients suggesting that GO makes a minimal contribution to the low relapse risk with ATO at least in standard risk disease.
In AML17 the lack of survival benefit resulted from the highly effective 
